PharmiWeb.com - Global Pharma News & Resources
11-Dec-2018

Global Thrombosis Drugs Market 2019-2023 | Introduction of Novel Oral Anticoagulants Drives Growth | Technavio

Technavio’s global thrombosis drugs market research report forecasts the market to grow at a CAGR of more than 9% during the forecast period.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181211005610/en/

Technavio has released a new market research report on the global thrombosis drugs market for the period 2019-2023. (Graphic: Business Wire)

The sedentary lifestyle will be one of the major trends in the global thrombosis drugs marketduring 2019-2023. The two common causes of thrombosis are old age and obesity. Obesity can either be genetic or environmental. A sedentary lifestyle is one of the major common causes of obesity in people. Little to no exercise in people affects the muscles and can lead to DVT. The blood flow in deep veins is affected when a person remains still for prolonged periods of time as the calf muscles do not contract, resulting in the formation of blood clots in deep veins.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

According to Technavio analysts, one of the key drivers for the global thrombosis drugs market is the introduction of novel oral anticoagulants:

Global thrombosis drugs market: Introduction of novel oral anticoagulants

Anticoagulants help in preventing the formation of harmful clots in blood vessels. Most of the early entrants in the anticoagulants space were administered through the parenteral route. But, this route of administration (RoA) was not popular among patients due to its non-friendly nature and thereby led to poor patient adherence. This led to the vendors in the thrombosis drugs market to develop and introduce novel oral anticoagulants during the last decade.

According to a senior analyst at Technavio for research onpharmaceuticals, “Treatments using vitamin K antagonists can result in the body permanently losing its ability to clot blood for prolonged periods of time. Hence, an increasing number of patients are choosing novel oral anticoagulants. Three of the highest-selling drugs for the treatment of thrombosis are novel oral anticoagulants. During the forecast period, the development and launch of such drugs are expected to result in the significant growth of the market.”

Global thrombosis drugs market: Segmentation analysis

This global thrombosis drugs market analysis report provides market segmentation by indication (pulmonary embolism and DVT) and by region (the Americas, APAC, and EMEA). This report provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Of the two major segments by indication, the pulmonary embolism segment held the largest thrombosis drugs market share in 2018, contributing to more than 58% of the market. This segment will dominate the global market throughout the forecast period.

The Americas held the largest share of the market in 2018, accounting for over 52% share. It was followed by EMEA and APAC respectively. The Americas is expected to dominate the market throughout the period 2019-2023.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181211005610/en/

Editor Details

Last Updated: 11-Dec-2018